To date, cost analyses of skin cancer detection and screening via total body skin examination (TBSE) have primarily focused on the costs of the visit, skin biopsies, and pathologic assessment of lesions.1,2 However, in addition to skin cancers, premalignant actinic keratoses (AKs) and benign lesions (acrochordons, verruca vulgaris, and seborrheic keratoses [SKs]) are likely to be identified and treated during TBSEs. Factoring in the costs of treating these lesions during skin cancer screening visits is important for evaluating the cost effectiveness of skin cancer screening in dermatology practices.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Anderson A, Matsumoto M, Secrest A, Saul MI, Ho J, Ferris LK. Cost of Treatment of Benign and Premalignant Lesions During Skin Cancer Screening. JAMA Dermatol. Published online June 09, 2021. doi:10.1001/jamadermatol.2021.1953
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: